Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction-Reference-Cited by-同舟云学术

Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction

Published:2021-03 Issue: Volume:153 Page:186-192
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Kunimasa Kei,Oka Toru,Hara Satoshi,Yamada Noriyuki,Oizumi Satoshi,Miyashita Yoshihiro,Kamada Risa,Funamoto Tomoya,Kawachi Hayato,Kawamura Takahisa,Inoue Takako,Kuhara Hanako,Tamiya Motohiro,Nishino Kazumi,Matsunaga Takashi,Imamura Fumio,Fujita Masashi,Kumagai Toru

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference40 articles.

1. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov,2014

2. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer;Mok;N Engl J Med,2017

3. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity;Ballard;Clin Cancer Res,2016

4. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials;Goss;Ann Oncol,2018

5. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3);Wu;J Clin Oncol,2018

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inorganic sulfides prevent osimertinib-induced mitochondrial dysfunction in human iPS cell-derived cardiomyocytes;Journal of Pharmacological Sciences;2024-10

2. Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer;Frontiers in Oncology;2024-07-12

3. Transcriptomics coupled with proteomics reveals osimertinib-induced myocardial mitochondrial dysfunction;Toxicology Letters;2024-06

4. Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer;Expert Opinion on Drug Safety;2023-12-13

5. A Case of Lung Adenocarcinoma Harboring EGFR Mutation with a Severe Decreased Ejection Fraction After the Administration of Osimertinib;Haigan;2023-10-20